Bibliography
- Mazur L, Opydo-Chanek M, Stojak M. Glufosfamide as a new oxazaphosphorine anticancer agent. Anticancer Drugs 2011;6:488-93
- Asta Medica Glufosfamide investigator's brochure
- Briasoulis E, Judson I, Pavlidis N, Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the EORTC Early Clinical Studies Group. J Clin Oncol 2000;18(20):3535-44
- Shimizu T, Okamoto I, Tamura K, Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. Cancer Chemother Pharmacol 2010;65(2):243-50
- Giaccone G, Smit EF, de Jonge M, Glufosfamide administered by 1-hour infusion as second line treatment for advanced non cell lung cancer; a phase II trial of the EORTC New Drug Development Group. Eur J Cancer 2004;40(5):667-72
- Briasoulis E, Pavlidis N, Terret C, Glufosfamide administered using a 1-hour infusion given as first line treatment for advanced pancreatic cancer. A phase II trial of the EORTC New Drug Development Group. Eur J Cancer 2003;39(16):2334-40
- Van den Bent MJ, Grisold W, Frappaz D, European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 2003;14(12):1732-4
- Therasse P, Arbuck SG, Eisenhauer EA, New Guidelines to evaluate the response to treatment in solid tumors. JNCI 2000;92(3):205-16
- Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80
- Chiorean EG, Dragovich T, Hamm J, A phase I dose escalation study of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother Pharamcol 2008;61(6):1019-26
- Chiorean EG, Dragovitch T, Hamm J, A phase II trial of glufosfamide in combination with gemcitabine in chemotherapy naive pancreatic adenocarcinoma. Am J Clin Oncol 2010;33(2):111-16
- Ciuleanu TE, Pavlovsky AV, Bodoky G, A randomized phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 2009;45(9):1589-96
- Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009;45(2):275-80
- Kindler HL, Niedzwiecki D, Hollis D, Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28(22):3617-22
- Kindler HL, Friberg G, Singh DA, Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-40
- Van den Bent MJ, Brandes AA, Rampling R, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27(8):1268-74